Auro Peptides Profile
Key Indicators
- Authorised Capital ₹ 300.10 Cr
as on 16-11-2024
- Paid Up Capital ₹ 270.85 Cr
as on 16-11-2024
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 141.42%
(FY 2023)
- Profit 58.63%
(FY 2023)
- Ebitda 126.53%
(FY 2023)
- Net Worth -10.32%
(FY 2023)
- Total Assets 58.18%
(FY 2023)
About Auro Peptides
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 300.10 Cr and a paid-up capital of Rs 270.85 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Auro Peptides Limited India is Mylandlahalli Ashwini as CFO. Mudiraj Rani, Naga Kesavarapu, Chandra Tirumalareddy, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TG2012PLC078350
- Company No.
078350
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2012
- Date of AGM
19 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Auro Peptides?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mylandlahalli Ashwini | CFO | 21-Mar-2024 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mudiraj Rani  | Director | 15-Jun-2022 | Current |
| Naga Kesavarapu | Director | 20-Jan-2023 | Current |
| Chandra Tirumalareddy | Whole-Time Director | 23-May-2019 | Current |
| Satakarni Makkapati | Director | 02-Nov-2021 | Current |
| Sivakumaran Meenakshisunderam | Director | 29-Sep-2017 | Current |
Financial Performance and Corporate Structure Insights of Auro Peptides.
Auro Peptides Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 141.42% increase. The company also saw a substantial improvement in profitability, with a 58.63% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Auro Peptides?
In 2023, Auro Peptides had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Curateq Biologics Private LimitedActive 4 years 7 months
Sivakumaran Meenakshisunderam is a mutual person
- Eugia Steriles Private LimitedActive 4 years 5 months
Sivakumaran Meenakshisunderam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Auro Peptides?
Auro Peptides has a workforce of 169 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Auro Peptides, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auro Peptides's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
